phase i/ii trial of adapt-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors
Published 3 months ago • 72 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
0:37
the future of adapt-001 in patients with solid tumors refractory to checkpoint inhibitors
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
5:33
cancer immune checkpoint inhibitors
-
3:29
pd-l1/pd-1 pathway: a security checkpoint
-
3:36
medi5752: first-in-human trial of a novel pd-1 and ctla-4 bispecific checkpoint inhibitor
-
13:53
immune checkpoint inhibitors & co-stimulatory molecules | presented by dr. philippe bedard
-
27:43
targeting the immune system with checkpoint inhibitors
-
12:12
immune checkpoint proteins
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
6:08
pd-1, pd-l1 role in immune system inhibition
-
3:29
checkpoint inhibitors
-
3:30
side effects of immune checkpoint inhibitors
-
4:00
earlier use of checkpoint inhibitors
-
1:52
what are checkpoint inhibitors
-
5:10
introduction to immune checkpoint inhibitor (ici) immunotherapy
-
14:42
managing toxicities associated with immune-checkpoint inhibitors
-
5:34
nephrectomy after complete response to immune checkpoint inhibitors for mrcc
-
0:50
cancer breakthrough! immune checkpoint inhibitor
-
1:56
medi5752: novel pd-1/ctla-4 bispecific checkpoint inhibitor for advanced solid tumors
-
1:00
immunotherapy: checkpoint inhibitors
-
1:51
checkpoint inhibitors: taking the brakes off the immune system
-
3:48
overcoming resistance to immune checkpoint inhibitors in nsclc